• PDF / 170,165 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 111 Downloads / 151 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: case report A 45-year-old man developed oesophagitis, nausea, constipation, leucopenia, neutropenia and lymphopenia following treatment with carboplatin and paclitaxel for stage IIIB lung adenocarcinoma. The man was diagnosed with HIV at the age of 34 years, when he was admitted for iliac fracture. Later, he was admitted for Pneumocystis pneumonia and started receiving (unspecified) treatment for AIDS. He remained stable until the age of 45 years, when he was diagnosed with stage IIIB lung adenocarcinoma. Thereafter, he started receiving weekly carboplatin, area under the curve-2, paclitaxel 40 mg/m2 and concurrent irradiation for a primary lesion [routes not stated]. Subsequently, he developed nonhaematological toxicities in the form of grade III oesophagitis, grade II nausea and grade I constipation, accompanied by haematological toxicities in the form of grade II leucopenia, grade I neutropenia and grade III lymphopenia [durations of treatments to reactions onsets not stated]. Following completion of the concurrent chemoradiotherapy, the tumour size reduced. Following improvement in the oesophagitis, he started receiving durvalumab, until the tumour progressed after 4 months. Thereafter, recurrent brain metastasis was resected; none of the forty-six genes showed significant genetic alteration. Thereafter, liver metastasis was noted. Therefore, he started receiving second line therapy with docetaxel and ramucirumab. However, after 6 months, the liver metastases progressed further. Hence, he started receiving third-line treatment with pemetrexed. However, after two administrations, the liver metastases became worse. Therefore, he started receiving fourth-line treatment with gimeracil/ oteracil/tegafur [TS-1]. He received palliative radiotherapy for the liver metastases. At the time of this report, he continued receiving gemcitabine [not all outcomes stated]. Kawai S, et al. Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer. Case Reports 803519432 in Oncology 13: 747-753, No. 2, 2020. Available from: URL: http://doi.org/10.1159/000507390

0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Dec 2020 No. 1833